Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eczema

- PMLiVE

UK survey reveals two-thirds of vitiligo patients struggle with mental health

The Vitiligo Society has launched a campaign to address the lack of awareness and understanding surrounding the condition

- PMLiVE

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

Pfizer’s Litfulo recommended by NICE as first treatment for severe alopecia areata

Up to 14,000 patients living with the autoimmune disease could benefit from NICE’s decision

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Almirall and Microsoft partner to accelerate digital transformation in medical dermatology

The alliance is aimed at advancing the research of solutions for dermatological diseases

- PMLiVE

Sanofi/Regeneron’s Dupixent gets US label update for atopic dermatitis

Dupixent’s label now includes data supporting its use in hand and foot atopic dermatitis

- PMLiVE

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis

More than 26 million people in the US are affected by the inflammatory skin disease

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links